Nasdaq warns Brainstorm Cell Therapeutics of MVLS deficiency; 180 days to comply

BRAINSTORM CELL THERAPEUTICS INC.

Received Nasdaq deficiency notice on July 18, 2024 for MVLS below $35M minimum.
Company has until January 14, 2025 to regain compliance by closing at $35M or more for 10 consecutive business days.
If not compliant by deadline, Nasdaq may delist BCLI common stock; company may appeal.
No immediate impact on trading; BCLI continues to trade on Nasdaq Capital Market.
Company intends to monitor and take reasonable measures to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.